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     ABSTRACT  56 
Introduction: Alectinib demonstrated clinical efficacy and an acceptable safety profile in two 57 
phase II studies (NP28761 and NP28673). Here we report pooled efficacy and safety data 58 
after 15 and 18 months’ longer follow-up than the respective primary analyses.   59 
 60 
Materials and methods: Enrolled patients had ALK-positive NSCLC and had progressed 61 
on, or were intolerant to, crizotinib. Patients received oral alectinib 600 mg twice daily. The 62 
primary endpoint in both studies was objective response rate (ORR) assessed by an 63 
independent review committee (IRC) using Response Evaluation Criteria in Solid Tumors 64 
(RECIST v1.1). Secondary endpoints included disease control rate (DCR); duration of 65 
response (DOR); progression-free survival (PFS); overall survival (OS); and safety. 66 
 67 
Results: The pooled dataset included 225 patients (n=138 NP28673; n=87 NP28761). The 68 
response-evaluable (RE) population included 189 patients (84%; n=122 NP28673; n=67 69 
NP28761). In the RE population, ORR by IRC was 51.3% (95% confidence interval [CI], 70 
44.0–58.6; all partial responses), DCR was 78.8% (95% CI, 72.3–84.4), and median DOR 71 
was 14.9 months (95% CI, 11.1–20.4) after 58% of events. Median PFS by IRC was 8.3 72 
months (95% CI, 7.0–11.3) and median OS was 26.0 months (95% CI, 21.4–not estimable). 73 
Grade ≥3 adverse events (AEs) occurred in 40% of patients, 6% withdrew treatment due to 74 
AEs and 33% had AEs leading to dose interruptions/modification.  75 
 76 
Conclusion: This pooled data analysis confirmed the robust systemic efficacy of alectinib in 77 
ALK-positive NSCLC with a durable response rate. Alectinib also had an acceptable safety 78 
profile with a longer duration of follow-up. 79 
 80 
Key Words:  Alectinib; Non-Small-Cell Lung Cancer; NP28673; NP28761; Pooled Analysis. 81 
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INTRODUCTION 83 
Non-small-cell lung cancer (NSCLC) harboring a chromosomal rearrangement of the 84 
anaplastic lymphoma kinase (ALK) gene (ALK-positive NSCLC), represents a distinct 85 
molecular subset of the disease, which affects approximately 5% of patients.1 Crizotinib is 86 
the current standard of care for ALK-positive NSCLC and has extended progression-free 87 
survival (PFS) compared with cytotoxic chemotherapy (10.9 months versus 7.7 months, 88 
respectively) in the first- and second-line treatment setting.2,3 Unfortunately, almost half of 89 
crizotinib-treated patients relapse within the first year. This is usually as a result of poor 90 
control of disease within the central nervous system (CNS), which is the most common site 91 
of disease progression (PD),4,5 or due to secondary ALK resistance mutations.6,7,8 92 
 93 
Second-generation ALK inhibitors have been developed with the aim of improving efficacy in 94 
patients with ALK-positive NSCLC, including those with CNS metastases. The ALK inhibitor 95 
ceritinib was granted accelerated approval by the US Food and Drug Administration (FDA) in 96 
2014 for use in patients with ALK-positive, metastatic NSCLC who had progressed on, or 97 
were intolerant to, crizotinib.9 The European Medicines Agency (EMA) subsequently 98 
approved ceritinib in 2015 for use in the same indication.10 The approvals were based on a 99 
phase I and phase II study of ceritinib in patients with ALK-positive NSCLC, which 100 
demonstrated median PFS of 5.7–6.9 months and objective response rates (ORRs) of 39–101 
56%.11,12 Recently, the FDA approval was extended to treatment-naïve patients with 102 
metastatic ALK-positive NSCLC.13 The extended approval was based on results from the 103 
ASCEND-4 trial, which demonstrated superior PFS with ceritinib versus platinum-104 
pemetrexed doublet chemotherapy in patients with treatment-naïve, ALK-positive NSCLC 105 
(median 16.6 vs 8.1 months; hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.42–0.73; 106 
p<0.0001);14 a similar trend was observed in patients with CNS metastases at baseline, but 107 
this was not significant. ORRs were improved with ceritinib versus chemotherapy, 108 
respectively, in the overall study population (73% vs 27%) and in those with measurable 109 
CNS disease at baseline (46% vs 21%).14 110 
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 111 
Alectinib is a potent and highly selective ALK inhibitor that has demonstrated both systemic 112 
and CNS efficacy in ALK-positive NSCLC in a number of studies.15–18 Alectinib was 113 
approved in Japan in 2014, for the treatment of ALK inhibitor-naïve patients with ALK-114 
positive NSCLC, following results of a phase I/II study (AF001-JP). This study reported a 115 
high ORR of 93.5% (95% CI 82–99); follow-up for this study is still ongoing with a 3-year 116 
PFS rate of 62% (95% CI 45–75).19 Similarly, significant clinical activity was reported with 117 
alectinib in two pivotal phase II studies, one global (NP28673; NCT01801111) and one North 118 
American (NP28761; NCT01871805), in patients with ALK-positive NSCLC who had 119 
received prior crizotinib. ORRs of 50.8% (95% CI 41.6–60.0) and 52.2% (95% CI 39.7–64.6) 120 
were observed in NP28673 and NP28761, respectively (data cut-off 27 April 2015), with 121 
median durations of response (DOR) of 14.1 months (95% CI 10.9–not estimable [NE]; 44% 122 
of events) and 13.5 months (95% CI 6.7–NE; 40% of events), respectively. Alectinib was 123 
well tolerated in the global and North American studies, as reflected by the rates of dose 124 
interruptions (23% and 36%, respectively), dose reductions (10% and 16%) and withdrawals 125 
due to adverse events (AEs) (9% and 2%, respectively) reported (27 April 2015 data cut-126 
off).17,18 Data from these two phase II studies led to the accelerated approval of alectinib in 127 
2015 by the FDA for the treatment of patients with ALK-positive NSCLC who have 128 
progressed on, or are intolerant to, crizotinib.20 Alectinib has also received conditional 129 
approval for the same patient population from the EMA. Data from the first-line, phase III, 130 
global ALEX study demonstrated that patients treated with alectinib had a longer PFS than 131 
patients treated with crizotinib.21 132 
 133 
Here, we present pooled efficacy and safety analyses from these phase II studies with 15 134 
and 18 months’ longer follow-up than the respective primary analyses for NP28761 (data 135 
cut-off of 22 January 2016 versus 24 October 2014) and NP28673 (data cut-off of 1 136 
February 2016 versus18 August 2014). 137 
METHODS 138 
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Study Design  139 
NP28673 and NP28761 were phase II, single-arm, open-label, multicenter studies. 140 
NP28673 was conducted across 16 countries at 56 sites and patients were enrolled between 141 
20 June 2013 and 23 April 2014. NP28761 was undertaken in 27 centers across the USA 142 
and Canada, with patients enrolled between 3 May 2012 and 4 August 2014; this timeframe 143 
also included a phase I dose-finding step, hence, the phase II portion of the study 144 
commenced on 4 September 2013. Both studies were undertaken in accordance with the 145 
principles of the Declaration of Helsinki and Good Clinical Practice Guidelines, and written 146 
informed consent was obtained from all patients. Full methodology for each study has been 147 
published previously.17,18  148 
 149 
Eligibility Criteria  150 
Both studies enrolled patients who were aged ≥18 years, with locally advanced or 151 
metastatic ALK-positive NSCLC as assessed by an FDA-approved fluorescence in situ 152 
hybridization test. Eligible patients had an Eastern Cooperative Oncology Group (ECOG) 153 
performance status (PS) of ≤2, and had progressed on crizotinib. Patients with 154 
asymptomatic baseline CNS metastases (treated or untreated with radiation) and those who 155 
had received prior chemotherapy were permitted to enroll into both studies. Patients were 156 
excluded if they had received prior ALK inhibitor treatment other than crizotinib.  157 
 158 
Study Treatment 159 
All patients received 600 mg oral alectinib twice daily with a meal, until PD, 160 
unacceptable toxicity, withdrawal or death. In both studies there was a minimum washout 161 
period of 7 days between the last dose of crizotinib and the first dose of alectinib.  162 
 163 
Study Endpoints  164 
The primary endpoint of the pooled analysis was ORR assessed by an Independent 165 
Review Committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) 166 
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v1.1. The secondary endpoints for both studies included disease control rate (DCR), DOR, 167 
PFS, overall survival (OS), and safety. CNS secondary endpoints were also evaluated 168 
including CNS ORR and CNS DOR, and will be reported in a separate analysis.   169 
 170 
Statistical Analysis  171 
Response endpoints were assessed in the response-evaluable (RE) population, 172 
which comprised patients with measurable disease at baseline who received at least one 173 
dose of alectinib. The safety population comprised all patients who received at least one 174 
dose of alectinib. ORR was defined as the proportion of patients achieving a best overall 175 
response of confirmed complete response (CR) or partial response (PR) in the RE 176 
population. PFS and OS were  assessed in the safety population. PFS was calculated from 177 
the date of first dose of alectinib until PD or death. OS was calculated from the date of first 178 
dose of alectinib until death. Time-to-event data (PFS, OS and DOR) were estimated using 179 
Kaplan-Meier analyses. 180 
 181 
RESULTS 182 
Patients  183 
The pooled dataset comprised 225 patients (138 patients from study NP28673 and 184 
87 patients from study NP28761) (Supplementary Fig. 1). The RE population according to 185 
IRC included 189 patients (84%), comprising 122 patients from study NP28673 and 67 186 
patients from study NP28761. Baseline characteristics were similar across both studies 187 
(Table 1). Briefly, median patient age was 53 years (range, 22–79); 67% of patients had an 188 
ECOG PS of 1/2 and the majority of patients were White (74%). Overall, 136 (60%) patients 189 
had baseline CNS metastases and 174 (77%) had received prior chemotherapy (Table 1).  190 
 191 
Efficacy  192 
At the data cut-off (NP28673:1 February 2016 and NP28761: 22 January 2016), 193 
median follow-up for the pooled dataset was 18.8 months (range 0.6–29.7). In the RE 194 
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population, the ORR by IRC was 51.3% (95% CI 44.0–58.6), with 97/189 patients achieving 195 
a PR and there were no CRs. Stable disease (SD) was reported in 52/189 patients (28%) 196 
giving a DCR of 78.8% (95% CI 72.3–84.4). Median DOR was 14.9 months (95% CI 11.1–197 
20.4) after 58% of events.  198 
 199 
Of the patients who had received prior chemotherapy in the RE population (n=148), 73 200 
(49%) achieved a PR; there were no CRs, giving an IRC-assessed ORR of 49.3% (95% CI 201 
41.0–57.7). In total, 44/148 patients had SD (30%), resulting in a DCR of 79.1% (95% CI 202 
71.6–85.3). The median DOR in this subgroup was also 14.9 months (95% CI 11.0–21.9) 203 
based on 59% of events.  204 
 205 
Overall, 24/41 (59%) chemotherapy-naïve patients in the RE population achieved a PR; 206 
there were no CRs, giving an IRC-assessed ORR of 58.5% (95% CI 42.1–73.7). SD was 207 
reported in 8/41 patients (20%) giving a DCR in this population of 78.0% (95% CI 62.4–208 
89.4). The median DOR was 11.2 months (95% CI 8.0–NE) after 54% of events. 209 
 210 
A subgroup analysis of IRC-assessed ORR was performed to evaluate different prognostic 211 
factors, including gender, race, ECOG PS, CNS metastases at baseline, smoking status and 212 
prior chemotherapy. Objective response rates were generally consistent across most 213 
subgroups. Patients with an ECOG PS 0 had a numerically higher response rate compared 214 
with patients with ECOG PS 1 or 2 (65.6% [95% CI 52.3–77.3] versus 45.0% [95% CI 35.6–215 
54.8] or 41.2% [95% CI 18.4–67.1], respectively). The analysis also showed a higher 216 
response rate in patients who were never-smokers at baseline compared with those who 217 
were past smokers (55.9% [95% CI 46.8–64.7] versus 39.0% [95% CI 26.5–52.6], 218 
respectively) (Table 2). However, it should be noted that the subgroups were relatively small 219 
and confidence intervals were overlapping.  220 
 221 
In the pooled population, 156/225 patients (69%) had a PFS event according to the IRC at 222 
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the data cut-off. The median PFS was 8.3 months (95% CI 7.0–11.3) (Fig. 1) and the 6 223 
month event-free rate was 59.9% (95% CI 53.5–66.4). For patients who had only received 224 
crizotinib treatment prior to receiving alectinib (51/225; 23%), the median PFS was 8.4 225 
months (95% 5.6–16.6). With regards to OS, 96/225 patients (43%) had an OS event at the 226 
data cut-off. The median OS was 26.0 months (95% CI 21.4–NE) and the 6 month event-227 
free rate was 85.3% (95% CI 80.6–89.9) (Fig. 2). 228 
 229 
Safety  230 
Safety was evaluated in the pooled safety population of 225 patients (138 patients 231 
from study NP28673 and 87 patients from study NP28761). The mean dose intensity of 232 
alectinib was 94.1%.  233 
 234 
AEs occurring at a frequency of >20% (any grade) were constipation (38%), fatigue (34%), 235 
peripheral edema (28%), myalgia (25%), nausea (23%), cough (21%) and headache (21%). 236 
A summary of AEs occurring at a frequency of >10% are shown in Table 3. Grade 3–5 AEs 237 
occurred in 40% of patients and the most common were dyspnea (4%), elevated levels of 238 
blood creatine phosphokinase (4%), alanine aminotransferase (3%) and aspartate 239 
aminotransferase (3%). Seven patients (3%) died during the study, including two cases of 240 
hemorrhage and one case each of dyspnea, endocarditis, intestinal perforation, pulmonary 241 
embolism, and unspecified death. Only two deaths (1%) were considered by the investigator 242 
to be treatment-related (hemorrhage and intestinal perforation).  243 
 244 
AEs leading to dose modification or interruptions occurred in 33% of patients (n=75), while 245 
AEs leading to treatment withdrawal were reported in 6% of patients (n=14) (Table 4).  246 
 247 
DISCUSSION 248 
Alectinib has demonstrated clinical systemic and CNS efficacy in two pivotal phase II 249 
trials, achieving high response rates and durable responses.17,18 In the present analysis, 250 
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efficacy and safety data were pooled from these phase II trials, with 15 and 18 months’ 251 
longer follow-up for NP28761 and NP28673, respectively. These data confirmed the clinical 252 
activity and acceptable safety profile of alectinib in patients with ALK-positive NSCLC, 253 
following treatment with crizotinib.  254 
 255 
Despite the differences in standard-of-care for ALK-positive NSCLC between the USA and 256 
the rest of the world, the patient populations in NP28761 and NP28673 were very similar, 257 
with 80% and 74% of patients progressing on prior chemotherapy and crizotinib, 258 
respectively. Other baseline characteristics were also very similar across the two studies 259 
including patient age (median 54 versus 52 years); proportion of male patients (45 versus 260 
44%); patients with an ECOG PS of 0/1 (90 versus 91%) and patients with baseline CNS 261 
disease (60 versus 61%) in the North American and global studies respectively, supporting 262 
the rationale for combining these datasets.  263 
 264 
The ORR of 51.3% that we observed in the present analysis is consistent with the ORRs 265 
reported in the individual primary and updated analyses of NP28673 (49.2% and 50.8%, 266 
respectively) and NP28761 (47.8% and 52.2%, respectively).17,18 In this pooled analysis, 267 
alectinib demonstrated efficacy regardless of prior treatment with chemotherapy, with an 268 
ORR of 49.3% for patients who received prior chemotherapy compared with 58.5% in 269 
patients who were chemotherapy-naïve.  270 
 271 
Overall, the safety profile of alectinib in this pooled analysis was consistent with data 272 
reported in the primary publications.17,18 Alectinib was well tolerated and the majority of AEs 273 
were grade 1/2 in severity, with only 1% of deaths reported as being treatment related. 274 
During the pooling of these study data, exposure-response analysis was also performed. 275 
Multivariate logistic regression and Cox proportional hazards analyses of the efficacy data 276 
demonstrated no statistically significant relationship between alectinib exposure and best 277 
overall response or PFS across the two studies, and logistic regression analysis 278 
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demonstrated no statistically significant relationship between alectinib exposure and safety 279 
endpoints.22 These exploratory analyses confirm that the alectinib dosing regimen of 600 mg 280 
twice daily provides exposures within the expected plateau range of response, supporting its 281 
selection as the global dosing regimen. 282 
 283 
Crizotinib was the first ALK inhibitor to be approved for the treatment of ALK-positive NSCLC 284 
and is the current standard of care. Crizotinib prolongs PFS, increases ORR and shows a 285 
greater improvement in global quality of life compared to chemotherapy in both previously-286 
treated and treatment-naïve, ALK-positive NSCLC.2,3 Ceritinib was also approved for the 287 
treatment of crizotinib-pretreated patients with ALK-positive NSCLC, after achieving ORR 288 
rates of 39–56% and a median PFS of 5.7–6.9 months in phase I and II studies.11,12 289 
Recently, ceritinib was also approved in the first-line setting for patients with ALK-positive 290 
NSCLC, based on superior PFS and ORRs versus chemotherapy reported in the ASCEND-4 291 
trial.14 The ORR and PFS for ceritinib are comparable with those of alectinib in this pooled 292 
analysis, but in the ASCEND-2 trial,12 ceritinib was associated with high rates of dose 293 
interruptions (76%), modifications or discontinuations (54%). In contrast, alectinib 294 
demonstrated an acceptable safety profile and good tolerability in this pooled analysis, as 295 
reflected by the rates of dose interruptions and modifications (33%) and low withdrawal rates 296 
(6%). A recent study of the ALK inhibitor brigatinib, in the same setting as the two alectinib 297 
studies presented here, showed ORR of 45–54% and median PFS of 9.2–12.9 months with 298 
doses of 90 mg once daily (q.d) or 90 mg q.d for 7 days followed by 180 mg q.d, 299 
respectively. Compared with alectinib, brigatinib showed comparable rates of dose 300 
reductions (7%) and dose interruptions (18%) due to AEs at the lower dose, however, at the 301 
higher dose, brigatinib showed greater rates of dose reductions (20%), dose interruptions 302 
(36%) and discontinuations (8%).23 303 
 304 
Here we report the systemic efficacy and safety of the pooled population, while an analysis 305 
of the activity of alectinib on CNS metastases in this pooled dataset has recently been 306 
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published.24 Alectinib achieved a CNS ORR of 64.0% (95% CI 49.2–77.1) with a CNS DCR 307 
of 90.0% (95% CI 78.2–96.7) and CNS DOR of 10.8 months (95% CI 78.2–90.8), showing 308 
good CNS efficacy.  309 
 310 
Two ongoing phase III studies are directly comparing the efficacy of alectinib with crizotinib 311 
in patients with ALK inhibitor-naïve ALK-positive NSCLC (ALEX, NCT02075840; J-ALEX, 312 
JapicCTI-132316). Following an interim analysis, results from the J-ALEX study were 313 
released early, as the primary endpoint of PFS demonstrated superiority compared with 314 
crizotinib treatment (HR 0.34 [99.6826% CI 0.17–0.70, stratified log-rank p<0.0001]; median 315 
PFS not reached [95% CI 20.3–NE] versus 10.2 months [95% CI 8.2–12.0], for alectinib 316 
versus crizotinib).25, 24 Grade 3/4 AEs were observed at a greater frequency in the crizotinib 317 
arm (52%) compared with the alectinib arm (27%) and rates of drug interruptions were lower 318 
with alectinib than with crizotinib (29% versus 74%, respectively). Primary data from the 319 
global ALEX study also showed that alectinib had a superior PFS compared with crizotinib 320 
(12-month event-free survival rate, 68.4% [95% CI, 61.0–75.9] with alectinib versus 48.7% 321 
[95% CI, 40.4–56.9] with crizotinib.21.  322 
 323 
In conclusion, results from this pooled analysis showed that alectinib 600 mg twice daily 324 
demonstrated clinical activity and was well tolerated in patients with ALK-positive NSCLC 325 
who had progressed on crizotinib. Efficacy was shown in patients who had received prior 326 
chemotherapy as well as in those who were chemotherapy-naïve.  327 
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TABLE 1. Demographic and Baseline Characteristics of the Pooled Population (ITT 418 
Population)  419 
 NP28761 
(n=87) 
NP28673 
(n=138) 
Difference 
Between 
Cohorts, % 
Pooled 
Population 
(N=225) 
Median age, years (range) 54 (29–79) 52 (22–79) 2 years 53 (22–79) 
Sex, n (%) 
   Male  
   Female 
 
39 (45) 
48 (55) 
 
61 (44) 
77 (56) 
 
1 
1 
 
100 (44) 
125 (56) 
ECOG PS, n (%) 
   0 
   1 
   2 
 
30 (34) 
48 (55) 
9 (10) 
 
44 (32) 
81 (59) 
13 (9) 
 
2 
4 
1 
 
74 (33) 
129 (57) 
22 (10) 
Race, n (%) 
  White  
   Asian  
   Other  
   Black/African American  
  Multiple 
   Unknown 
   American Indian/Alaska 
Native 
 
73 (84) 
7 (8) 
3 (3) 
3 (3) 
1 (1) 
0 
0 
 
93 (67) 
36 (26) 
4 (3) 
1 (0.7) 
0 (0) 
3 (2) 
1 (0.7) 
 
17 
18 
0 
2.3 
1 
2 
0.7 
 
166 (74) 
43 (19) 
7 (3) 
4 (2) 
7 (3) 
1 (0.4) 
1 (0.4) 
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CNS metastases, n (%) 
   Yes  
   No  
 
52 (60) 
35 (40) 
 
84 (61) 
54 (39) 
 
1 
1 
 
136 (60) 
89 (40) 
Histology, n (%) 
   Adenocarcinoma 
   Other  
 
82 (94) 
5 (6) 
 
133 (96) 
5 (4) 
 
2 
2 
 
215 (96) 
10 (4) 
Prior chemotherapy, n (%) 
   Yes 
   No  
 
64 (74) 
23 (26) 
 
110 (80) 
28 (20) 
 
6 
6 
 
174 (77) 
51 (23) 
Crizotinib + prior therapies 
    Crizotinib only 
   +1 therapy 
   +2 therapies 
   +3 therapies 
   +4 therapies 
   +5 therapies 
   ≥6 therapies 
 
23 (26) 
0 
19 (22) 
18 (21) 
14 (16) 
8 (9) 
5 (6) 
 
28 (20) 
52 (38) 
16 (12) 
17 (12) 
16 (12) 
4 (3) 
5 (4) 
 
6 
38 
10 
9 
4 
6 
2 
 
51 (23) 
52 (23) 
35 (16) 
35 (16) 
30 (13) 
12 (5) 
10 (4) 
Smoking status  
   Active smoker  
   Past smoker 
   Never-smoker  
 
0 
33 (38) 
54 (62) 
 
3 (2) 
39 (28) 
96 (70) 
 
2 
10 
8 
 
3 (1) 
72 (32) 
150 (67) 
CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; PS, 420 
performance status. 421 
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TABLE 2. Subgroup Analyses of IRC Objective Response Rate in the Pooled Population  422 
(IRC RE Population) 423 
 
Patients Per 
Subgroup  
(n=189) 
Responders Per Subgroup 
n (%) 95% CI 
Sex 
   Male  
   Female 
 
88 
101 
 
46 (52.3) 
51 (50.5) 
 
41.4–63.0 
40.4–60.6 
Race 
   White  
   Asian  
   Other 
 
137 
38 
14 
 
70 (51.1) 
23 (60.5) 
4 (28.6) 
 
42.4–59.7 
43.4–76.0 
8.4–58.1 
ECOG PS at baseline 
   0 
   1 
   2 
 
61 
111 
17 
 
40 (65.6) 
50 (45.0) 
7 (41.2) 
 
52.3–77.3 
35.6–54.8 
18.4–67.1 
CNS metastases at 
baseline 
   Yes  
   No  
 
113 
76 
 
55 (48.7) 
42 (55.3) 
 
39.2–58.3 
43.4–66.7 
Prior chemotherapy 
   Yes 
   No  
 
148 
41 
 
73 (49.3) 
24 (58.5) 
 
41.0–57.7 
42.1–73.7 
Number of prior regimens 
   1–2 
   3–9 
 
89 
100 
 
48 (53.9) 
49 (49.0) 
 
43.0–64.6 
38.9–59.2 
Smoking status at 
screening  
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   Active smoker  
   Past smoker 
   Never-smoker  
3 
59 
127 
3 (100.0) 
23 (39.0) 
71 (55.9) 
29.2–100.0 
26.5–52.6 
46.8–64.7 
Time on prior crizotinib 
   ≤ median  
   ≥ median 
 
105 
84 
 
48 (45.7) 
49 (58.3) 
 
36.0–55.7 
47.1–69.0 
 
Best response on crizotinib  
   Complete response 
   Partial response 
   Stable disease 
   Progressive disease 
   Unknown/N/A/NE  
    
   
 
1 
           84 
43 
47 
14 
 
 
1 (100) 
50 (59.5) 
             19 (44.2) 
21 (44.7) 
6 (42.9) 
 
 
2.5–100.0 
48.3–70.1 
29.1–60.1 
30.2–59.9 
17.7–71.1 
 424 
CI, confidence interval; CNS, central nervous system; ECOG, Eastern Cooperative 425 
Oncology Group; NE, not evaluable; N/A, not applicable; PS, performance status; RE, 426 
response evaluable.   427 
 428 
 429 
 430 
 431 
 432 
 433 
 434 
Table 3. Adverse Events with an Incidence Rate of >10% in the Pooled Studies (ITT 435 
Population) 436 
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Adverse Event, n (%) 
NP28761 
(n=87) 
NP28673 
(n=138) 
Difference 
Between 
Cohorts, % 
Pooled 
Population 
(N=225) 
Patients with ≥1 adverse event 84 (97) 135 (98) 1 219 (97) 
Constipation 32 (37) 53 (38) 1 85 (38) 
Fatigue 33 (38) 43 (31) 7 76 (34) 
Peripheral edema 22 (25) 41 (30) 5 63 (28) 
Myalgia 22 (25) 35 (25) 0 57 (25) 
Nausea 21 (24) 30 (22) 2 51 (23) 
Cough 18 (21) 30 (22) 1 48 (21) 
Headache 21 (24) 26 (19) 5 47 (21) 
Diarrhea 20 (23) 22 (16) 7 42 (19) 
Dyspnea 17 (20) 23 (17) 3 40 (18) 
Increased aspartate 
aminotransferase 
18 (21) 18 (13) 8 36 (16) 
Anemia 17 (20) 16 (12) 8 33 (15) 
Weight increased 16 (18) 17 (12) 6 33 (15) 
Asthenia 2 (2) 30 (22) 20 32 (14) 
Upper respiratory tract infection  13 (15) 19 (14) 1 32 (14) 
Vomiting  11 (13) 21 (15) 2 32 (14) 
Increased alanine 
aminotransferase 
16 (18) 15 (11) 7 31 (14) 
Rash 8 (9) 22 (16) 7 30 (13) 
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Back pain  10 (11) 18 (13) 2 28 (12) 
Increased blood bilirubin 9 (10) 18 (13) 3 27 (12) 
Increased blood creatinine 
phosphokinase 
20 (23) 6 (4) 19 26 (12) 
Dizziness 11 (13) 15 (11) 2 26 (12) 
Photosensitivity reaction  10 (11) 16 (12) 1 26 (12) 
Arthralgia 10 (11) 15 (11) 0 25 (11) 
Insomnia 11 (13) 12 (9) 4 23 (10) 
Decreased appetite 5 (6) 17 (12) 6 22 (10) 
Upper abdominal pain 4 (5) 17 (12) 7 21 (9) 
Nasopharyngitis  3 (3) 16 (12) 9 19 (8) 
Increased blood alkaline 
phosphatase 
12 (14) 5 (4) 10 17 (8) 
Hypokalemia 9 (10) 7 (5) 5 16 (7) 
Oropharyngeal pain  2 (2) 14 (10) 8 16 (7) 
Hypertriglyceridemia  11 (13) 0 13 11 (5) 
 437 
 438 
 439 
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Table 4. Adverse Events Leading to Dose Modification, Interruption or Withdrawal in the 440 
Pooled Studies (ITT Population). 441 
Outcome, n (%) 
NP28761  
(n=87) 
NP28673  
(n=138) 
Pooled Population 
(N=225) 
AE leading to withdrawal from 
study 
2 (2) 12 (9) 14 (6) 
AE leading to withdrawal from 
treatment 2 (2) 12 (9) 14 (6) 
AE leading to dose 
modification or interruption 37 (43) 38 (28) 75 (33) 
Serious AE leading to 
withdrawal from treatment 1 (1) 8 (6) 9 (4) 
Serious AE leading to dose 
modification or interruption 9 (10) 13 (9) 22 (10) 
Related AE leading to 
withdrawal from treatment 2 (2) 8 (6) 10 (4) 
Related AE leading to dose 
modification or interruption 24 (28) 23 (17) 47 (21) 
AE, adverse event 442 
 443 
 444 
  445 
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FIGURE LEGENDS 446 
 447 
FIGURE 1. IRC Progression-free survival of the pooled population (ITT Population, N=225). 448 
 449 
FIGURE 2. Overall survival of the pooled population (ITT Population, N=225). 450 
 451 
 452 
 453 
SUPPLEMENTARY FIGU RE 1. CONSORT diagram  454 
*IRC RE population defined as patients with measurable disease at baseline according to the IRC. 455 
(Not possible to include information regarding the reason for treatment discontinuations in either 456 
study, as these data are not availble). 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
 465 
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